ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results

Transplant Proc. 2003 Sep;35(6):2100-1. doi: 10.1016/s0041-1345(03)00679-1.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antilymphocyte Serum / therapeutic use*
  • Basiliximab
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Graft Survival / immunology*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Isoantibodies / blood
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / mortality
  • Male
  • Middle Aged
  • Postoperative Complications / classification
  • Postoperative Complications / epidemiology
  • Recombinant Fusion Proteins*
  • Survival Analysis
  • Tacrolimus / therapeutic use
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Isoantibodies
  • Recombinant Fusion Proteins
  • Basiliximab
  • Tacrolimus